| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1158/1078-0432.CCR-05-2518 |
| P698 | PubMed publication ID | 16609049 |
| P50 | author | Alexander J. Lazar | Q37838894 |
| P2093 | author name string | Helen Wu | |
| Hensin Tsao | |||
| Frank G Haluska | |||
| Vikas Goel | |||
| Frank S Haluska | |||
| P2860 | cites work | Mutations of the BRAF gene in human cancer | Q27860760 |
| P433 | issue | 7 Pt 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2301s-2307s | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Genetic alterations in signaling pathways in melanoma | |
| P478 | volume | 12 |
| Q37937344 | A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options. |
| Q37815139 | A new era: melanoma genetics and therapeutics |
| Q36944047 | A novel AKT3 mutation in melanoma tumours and cell lines |
| Q35093992 | A phase II study of gefitinib in patients with metastatic melanoma |
| Q53701225 | AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. |
| Q24601008 | Analysis of the genome to personalize therapy for melanoma |
| Q38854630 | Antiproliferative Effect of Rottlerin on Sk-Mel-28 Melanoma Cells |
| Q39890111 | BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. |
| Q42733647 | BRAF targeted therapy changes the treatment paradigm in melanoma |
| Q38520679 | BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation |
| Q39954044 | C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells |
| Q37662627 | CTGF is a therapeutic target for metastatic melanoma. |
| Q37114128 | Cancer stem cells and human malignant melanoma |
| Q35833179 | Cisplatin fails to induce puma mediated apoptosis in mucosal melanomas |
| Q44004637 | Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma |
| Q33968131 | Conditional ablation of Ikkb inhibits melanoma tumor development in mice |
| Q84392766 | Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis |
| Q37375271 | Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells |
| Q39634158 | Design, synthesis, and structure-activity relationships of 3-ethynyl-1H-indazoles as inhibitors of the phosphatidylinositol 3-kinase signaling pathway |
| Q37384015 | Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. |
| Q39712781 | Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. |
| Q45700846 | E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression |
| Q39917232 | E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway |
| Q33793145 | Engineering a waste management enzyme to overcome cancer resistance to apoptosis: adding DNase1 to the anti-cancer toolbox |
| Q28078465 | Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility |
| Q40222383 | Expression of a metastatic phenotype in IFNs-primed/TNFalpha-activated B16 murine melanoma cells: role of JAK1/PKCdelta signal transduction factors |
| Q45861923 | GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system |
| Q39226193 | Genotype-selective combination therapies for melanoma identified by high-throughput drug screening |
| Q34667738 | Genotyping of cutaneous melanoma |
| Q37152975 | Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma |
| Q45803765 | High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma |
| Q30437344 | Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy |
| Q34452761 | Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro |
| Q36990701 | Issues affecting molecular staging in the management of patients with melanoma |
| Q36273561 | Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling. |
| Q21245465 | Main roads to melanoma |
| Q42190258 | Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice |
| Q36828214 | Melanoma invasion - current knowledge and future directions |
| Q35871461 | Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma |
| Q57781575 | Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma |
| Q38093446 | Molecular and cellular pathogenesis of melanoma initiation and progression. |
| Q33803248 | Molecular designing and in silico evaluation of darunavir derivatives as anticancer agents |
| Q35916919 | NF-κB as potential target in the treatment of melanoma |
| Q38148747 | Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma |
| Q35670683 | New Perspectives of "omics" Applications in Melanoma Research |
| Q39928689 | Notch1 is an effector of Akt and hypoxia in melanoma development |
| Q39037222 | Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy |
| Q82021676 | Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence |
| Q39943645 | Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. |
| Q41825555 | Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. |
| Q46095420 | PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation |
| Q47818895 | Pathology and genomics of pediatric melanoma: A critical reexamination and new insights. |
| Q35906375 | Pathway aberrations of murine melanoma cells observed in Paired-End diTag transcriptomes |
| Q34489987 | Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells |
| Q37716504 | Phosphorylated 4E-BP1 is associated with poor survival in melanoma |
| Q21245756 | PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway |
| Q35043887 | Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells |
| Q58787888 | Primary Mucosal Melanoma of the Stomach |
| Q42071086 | Primary dermal melanoma in a patient with a history of multiple malignancies: a case report with molecular characterization. |
| Q39199650 | Prognostic significance of Fbw7 in human melanoma and its role in cell migration |
| Q37656270 | Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. |
| Q30875021 | Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy |
| Q84759300 | SKI knockdown inhibits human melanoma tumor growth in vivo |
| Q35839745 | SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients. |
| Q37555793 | Small molecules and targeted therapies in distant metastatic disease. |
| Q33693906 | State of melanoma: an historic overview of a field in transition |
| Q30435893 | Strategies and challenges in eliciting immunity to melanoma |
| Q39875693 | Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells |
| Q39370488 | Synthesis and antitumor activity of inositol phosphotriester analogues |
| Q38646114 | Targeted Therapy for Melanoma |
| Q39968250 | Targeting lipid rafts inhibits protein kinase B by disrupting calcium homeostasis and attenuates malignant properties of melanoma cells |
| Q38718460 | The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors |
| Q37290440 | The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics |
| Q30252521 | The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status |
| Q54572747 | The risk factor of gallbladder cancer: hyperplasia of mucous epithelium caused by gallstones associates with p16/CyclinD1/CDK4 pathway. |
| Q36562233 | Therapeutic targets in melanoma: map kinase pathway |
| Q37873464 | Therapy for metastatic melanoma: an overview and update |
| Q36918133 | Toxicogenomics of A375 human malignant melanoma cells |
| Q35581006 | Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo |
| Q37034487 | Understanding signaling cascades in melanoma |
| Q37328383 | Wnt and related signaling pathways in melanomagenesis. |
Search more.